{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T16:03:43Z","timestamp":1778601823679,"version":"3.51.4"},"reference-count":112,"publisher":"Informa UK Limited","issue":"3","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Emerging Drugs"],"published-print":{"date-parts":[[2022,7,3]]},"DOI":"10.1080\/14728214.2022.2110240","type":"journal-article","created":{"date-parts":[[2022,8,4]],"date-time":"2022-08-04T12:30:51Z","timestamp":1659616251000},"page":"321-331","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":7,"title":["Emerging drugs for the treatment of glaucoma: a review of phase II &amp; III trials"],"prefix":"10.1080","volume":"27","author":[{"given":"Tyler M.","family":"Kaplan","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, Mayo Clinic, Rochester, MN, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arthur J.","family":"Sit","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Mayo Clinic, Rochester, MN, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2022,8,12]]},"reference":[{"key":"cit0001","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2020.06.003"},{"key":"cit0002","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.3192"},{"key":"cit0003","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S44708"},{"key":"cit0004","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2020.1795130"},{"key":"cit0005","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2019.0044"},{"key":"cit0006","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.63.2.15"},{"key":"cit0007","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.2005.081224"},{"key":"cit0008","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2011.06.004"},{"key":"cit0009","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2015.09.005"},{"key":"cit0010","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-158-4-201302190-00008"},{"key":"cit0011","unstructured":"Tanna A. BCSC 10: glaucoma. 2021."},{"key":"cit0012","doi-asserted-by":"publisher","DOI":"10.2174\/1874364101004010052"},{"key":"cit0013","doi-asserted-by":"publisher","DOI":"10.1097\/IIO.0b013e31821e5cea"},{"key":"cit0014","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9394(98)00436-X"},{"key":"cit0015","doi-asserted-by":"publisher","DOI":"10.1016\/j.exer.2016.01.017"},{"key":"cit0016","unstructured":"Nicox Visible Science. Nicox reports positive results of secondary analyses from phase 2 trial further highlighting potential of NCX 470 in glaucoma. 2021."},{"key":"cit0017","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-018-1016-1"},{"key":"cit0018","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.17-22745"},{"key":"cit0019","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2017.0146"},{"key":"cit0020","doi-asserted-by":"publisher","DOI":"10.1097\/IJG.0000000000001836"},{"key":"cit0021","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2021.12.011"},{"key":"cit0022","doi-asserted-by":"publisher","DOI":"10.2147\/JEP.S281187"},{"key":"cit0023","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2021.0077"},{"key":"cit0024","doi-asserted-by":"publisher","DOI":"10.1167\/tvst.11.1.7"},{"key":"cit0025","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.61.14.12"},{"key":"cit0026","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.15-17190"},{"key":"cit0027","unstructured":"Nicox Visible Science. Nicox\u2019s NCX 470 demonstrates significant intraocular pressure lowering in dolomites phase 2 glaucoma trial. Available from: globenewswire.com."},{"key":"cit0028","unstructured":"Helzner J. Nicox begins second phase 3 trial of NCX 470. Available from: glaucomaphysician.net."},{"key":"cit0029","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2013.216"},{"key":"cit0030","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2013.217"},{"key":"cit0031","unstructured":"Sylentis. Sylentis announces top-line results from phase II study SYLTAG for RNAi drug bamosiran (SYL040012) in glaucoma. Available from: https:\/\/www.sylentis.com."},{"key":"cit0032","unstructured":"Qlaris. Qlaris bio enrolls first patient in phase 1\/2 Studies of QLS-101, an investigational therapy designed to lower episcleral venous pressure (EVP) in patients with glaucoma. Available from: businesswire.com."},{"key":"cit0033","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.6b00406"},{"key":"cit0034","doi-asserted-by":"publisher","DOI":"10.1016\/j.exer.2016.04.020"},{"key":"cit0035","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0141783"},{"key":"cit0036","doi-asserted-by":"publisher","DOI":"10.1177\/11206721211018365"},{"key":"cit0037","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2008.08.051"},{"key":"cit0038","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(01)00873-9"},{"key":"cit0039","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2016.03.016"},{"key":"cit0040","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2005.02.013"},{"key":"cit0041","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32213-X"},{"key":"cit0042","doi-asserted-by":"publisher","DOI":"10.1016\/j.survophthal.2008.08.010"},{"key":"cit0043","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.03-0990"},{"key":"cit0044","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.02-1281"},{"key":"cit0045","doi-asserted-by":"publisher","DOI":"10.1177\/1060028014548569"},{"key":"cit0046","doi-asserted-by":"publisher","DOI":"10.1016\/S0039-6257(02)00307-7"},{"key":"cit0047","doi-asserted-by":"publisher","DOI":"10.1016\/S0039-6257(97)80020-3"},{"key":"cit0048","doi-asserted-by":"publisher","DOI":"10.1097\/IOP.0b013e31817d81df"},{"key":"cit0049","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-72538-x"},{"key":"cit0050","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.10064"},{"key":"cit0051","doi-asserted-by":"publisher","DOI":"10.1097\/IJG.0000000000000929"},{"key":"cit0052","doi-asserted-by":"publisher","DOI":"10.1016\/j.survophthal.2020.02.004"},{"key":"cit0053","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9394(14)75005-6"},{"key":"cit0054","doi-asserted-by":"publisher","DOI":"10.1016\/0039-6257(83)90152-2"},{"key":"cit0055","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9394(86)90942-6"},{"key":"cit0056","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(99)90497-9"},{"key":"cit0057","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2004.04.022"},{"issue":"12","key":"cit0058","first-page":"7623","volume":"54","author":"Nau CB","year":"2013","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"13","key":"cit0059","first-page":"3145","volume":"32","author":"Brubaker RF","year":"1991","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"cit0060","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2019.02.014"},{"key":"cit0061","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2021.0068"},{"key":"cit0062","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199040010-00005"},{"key":"cit0063","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.1997.01100150047008"},{"key":"cit0064","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2005.01.042"},{"key":"cit0065","doi-asserted-by":"publisher","DOI":"10.1136\/bmjresp-2020-000557"},{"key":"cit0066","doi-asserted-by":"publisher","DOI":"10.1177\/1060028018782479"},{"key":"cit0067","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.733080"},{"key":"cit0068","doi-asserted-by":"publisher","DOI":"10.1097\/00061198-199708000-00010"},{"key":"cit0069","doi-asserted-by":"publisher","DOI":"10.1089\/jop.1990.6.251"},{"key":"cit0070","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.1997.01100160017002"},{"key":"cit0071","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2010.03.026"},{"key":"cit0072","doi-asserted-by":"publisher","DOI":"10.1038\/sj.eye.6700520"},{"key":"cit0073","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2018.04.040"},{"key":"cit0074","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2017.0138"},{"key":"cit0075","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2021.01.019"},{"key":"cit0076","doi-asserted-by":"publisher","DOI":"10.1097\/IJG.0000000000001634"},{"key":"cit0077","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2019.01.003"},{"key":"cit0078","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.1.1118.811"},{"key":"cit0079","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.1996.01100130578015"},{"key":"cit0080","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(82)34866-6"},{"key":"cit0081","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-010-0070-1"},{"key":"cit0082","first-page":"40","volume":"110","author":"Baudouin C","year":"2012","journal-title":"Trans Am Ophthalmol Soc"},{"key":"cit0083","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2014.05.013"},{"issue":"2","key":"cit0084","volume":"47","author":"Charters L","year":"2022","journal-title":"Ophthalmol Times"},{"key":"cit0085","unstructured":"Reports MI. Glaucoma treatment market - Growth, trends, COVID-19 impact, and forecasts (2022 \u2013 2027). 2021."},{"key":"cit0086","unstructured":"Delveinsight. Glaucoma - Market insight, epidemiology and market forecast - 2032. 2022."},{"key":"cit0087","doi-asserted-by":"publisher","DOI":"10.1016\/S0039-6257(03)00003-1"},{"key":"cit0088","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-95768-z"},{"key":"cit0089","doi-asserted-by":"publisher","DOI":"10.1007\/s10384-021-00868-y"},{"key":"cit0090","doi-asserted-by":"publisher","DOI":"10.1111\/bph.14328"},{"key":"cit0091","doi-asserted-by":"publisher","DOI":"10.1016\/j.exer.2011.05.003"},{"key":"cit0092","volume":"62","author":"Steel C","year":"2021","journal-title":"Invest Ophthalmol Vis Sci Ophthalmol Vis Sci"},{"key":"cit0093","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.17-22538"},{"key":"cit0094","doi-asserted-by":"publisher","DOI":"10.3109\/02713683.2011.593725"},{"key":"cit0095","doi-asserted-by":"publisher","DOI":"10.1097\/ICO.0b013e3182523f40"},{"key":"cit0096","unstructured":"Santen Pharmaceutical. Santen and ube announces launch of glaucoma and ocular hypertension treatment EYBELIS ophthalmic solution 0.002% in South Korea. 2021."},{"key":"cit0097","unstructured":"Santen Pharmaceutical. Santen and ube announces U.S. FDA acceptance of new drug application for STN10117 (DE-117) (JAN: omidenepag isopropyl) as a treatment for patients with glaucoma and ocular hypertension. 2021."},{"key":"cit0098","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S333042"},{"key":"cit0099","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S271789"},{"key":"cit0100","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.8b00808"},{"key":"cit0101","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2020.0003"},{"key":"cit0102","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.63.2.24"},{"key":"cit0103","unstructured":"Santen Pharmaceutical. US ophthalmic pipeline and clinical trials. Available from: Santenusa.com."},{"key":"cit0104","unstructured":"Pharmaceuticals A. No title. Available from: globenewswire.com."},{"issue":"12","key":"cit0105","volume":"57","author":"Gonzalez V","year":"2016","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"cit0106","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2020.0137"},{"key":"cit0107","doi-asserted-by":"publisher","DOI":"10.1097\/ICO.0000000000002694"},{"key":"cit0108","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0231841"},{"key":"cit0109","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2013.0222"},{"key":"cit0110","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2014-305908"},{"key":"cit0111","doi-asserted-by":"publisher","DOI":"10.1097\/IJG.0000000000000449"},{"key":"cit0112","doi-asserted-by":"publisher","DOI":"10.1097\/IJG.0000000000002030"}],"container-title":["Expert Opinion on Emerging Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14728214.2022.2110240","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,5]],"date-time":"2022-11-05T07:36:05Z","timestamp":1667633765000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14728214.2022.2110240"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,3]]},"references-count":112,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,7,3]]}},"alternative-id":["10.1080\/14728214.2022.2110240"],"URL":"https:\/\/doi.org\/10.1080\/14728214.2022.2110240","relation":{},"ISSN":["1472-8214","1744-7623"],"issn-type":[{"value":"1472-8214","type":"print"},{"value":"1744-7623","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,3]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iemd20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iemd20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2022-06-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-08-02","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-08-12","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}